

**Department of Planning and Budget**  
**2025 General Assembly Session**  
**State Fiscal Impact Statement**

---

**PUBLISHED: 2/19/2025 4:40 PM**

**ORIGINAL**

**Bill Number:** HB1989S1

**Patron:** Askew

**Bill Title:** Medical cannabis program; product labels; delivery

**Bill Summary:** Changes the requirements for what is included on medical cannabis product labels affixed by pharmaceutical processors to include (i) the total milligrams of tetrahydrocannabinol and cannabidiol included in the edible cannabis product or topical cannabis product, both defined in the bill; (ii) the number of milligrams of tetrahydrocannabinol and cannabidiol in each serving of the edible cannabis product or topical cannabis product; and (iii) the total percentage of tetrahydrocannabinol and cannabidiol included in the inhalable cannabis product, defined in the bill. Under current law, the product label of any medical cannabis product is required to include the total percentage and milligrams of tetrahydrocannabinol and cannabidiol included in the product and the number of milligrams of tetrahydrocannabinol and cannabidiol in each serving.

The bill also allows a pharmaceutical processor or cannabis dispensing facility to dispense or deliver cannabis products in person to a patient or such patient's registered agent, parent, or legal guardian at any residence or business at which such patient or such patient's registered agent, parent, or legal guardian is lawfully permitted to receive deliveries. However, the bill prohibits dispensing or delivering cannabis products to any public gathering places and requires all delivery agents to comply with the provisions of this bill and all Cannabis Control Authority (CCA) Board regulations.

**Budget Amendment Necessary:** No.

**Items Impacted:** N/A

**Explanation:** N/A

**Fiscal Summary:** No material state fiscal impact.

**Fiscal Analysis:** According to the CCA, this bill is not expected to have a material fiscal impact on agency operations.

**Other:** None.